Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARGON: Enerzair Breezhaler vs Salmeterol/Fluticasone + Tiotropium in Uncontrolled Asthma
NCT03158311Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2018
- Primary completion
- Jul 2019
- Modality
- Orthosteric Ligands
- Countries
- 20
01
Overview
Phase 3, randomised, open-label trial of indacaterol acetate + glycopyrronium bromide + mometasone furoate in asthma (3 arms), sponsored by Novartis. Primary endpoint: Asthma Quality of Life Questionnaire Total Score at 24 weeks. Started Feb 2018; status: completed.
02
Drugs
indacaterol acetate + glycopyrronium bromide + mometasone furoate
03
Conditions
asthma
Beyond the preview
Go deeper on NCT03158311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03158311.